Kits Eyecare Balans Gezondheid

Financiële gezondheid criteriumcontroles 5/6

Kits Eyecare heeft een totaal eigen vermogen van CA$53.3M en een totale schuld van CA$7.5M, wat de schuld-eigenvermogensverhouding op 14.1% brengt. De totale activa en totale passiva bedragen respectievelijk CA$94.9M en CA$41.6M. De EBIT Kits Eyecare is CA$578.0K waardoor de rentedekking 0.8 is. Het heeft contanten en kortetermijnbeleggingen van CA$19.1M.

Belangrijke informatie

14.1%

Verhouding schuld/eigen vermogen

CA$7.52m

Schuld

Rente dekkingsratio	0.8x
Contant	CA$19.15m
Aandelen	CA$53.32m
Totaal verplichtingen	CA$41.58m
Totaal activa	CA$94.90m

Recente financiële gezondheidsupdates

Geen updates

Recent updates

Kits Eyecare Ltd. (TSE:KITS) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Nov 08

Kits Eyecare Ltd. (TSE:KITS) Stocks Shoot Up 28% But Its P/S Still Looks Reasonable

Aug 20

Why Investors Shouldn't Be Surprised By Kits Eyecare Ltd.'s (TSE:KITS) 33% Share Price Surge

Jun 08

An Intrinsic Calculation For Kits Eyecare Ltd. (TSE:KITS) Suggests It's 44% Undervalued

Jun 04

Revenues Tell The Story For Kits Eyecare Ltd. (TSE:KITS)

Dec 27

With Kits Eyecare Ltd. (TSE:KITS) It Looks Like You'll Get What You Pay For

Jun 13

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( CA$39.0M ) KITS } overtreffen de korte termijn passiva ( CA$32.4M ).

Langlopende schulden: De kortetermijnactiva KITS ( CA$39.0M ) overtreffen de langetermijnschulden ( CA$9.1M ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: KITS heeft meer geld in kas dan de totale schuld.

Schuld verminderen: Er zijn onvoldoende gegevens om te bepalen of de schuld/eigen vermogen-ratio van KITS de afgelopen 5 jaar is gedaald.

Balans

Analyse van de cashflow

Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.

Stabiele cash runway: Terwijl het verlieslatende KITS voldoende cash runway heeft voor meer dan 3 jaar, als het zijn huidige positieve vrije kasstroom-niveau behoudt.

Voorspelling contante baan: KITS is verlieslatend, maar heeft voldoende kasmiddelen voor meer dan 3 jaar, omdat de vrije kasstroom positief is en met 37.6 % per jaar groeit.

Kits Eyecare Balans Gezondheid

Financiële gezondheid criteriumcontroles 5/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Recent updates

Kits Eyecare Ltd. (TSE:KITS) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Third quarter 2024 earnings released: EPS: CA$0.004 (vs CA$0.015 in 3Q 2023)

Kits Eyecare Provides Earnings Guidance for the Fourth Quarter of 2024

Consensus EPS estimates increase by 25%

Co-Founder recently sold CA$1.4m worth of stock

Kits Eyecare Ltd. to Report Q3, 2024 Results on Nov 06, 2024

Consensus EPS estimates increase by 13%

New minor risk - Insider selling

Co-Founder recently sold CA$8.4m worth of stock

Kits Eyecare Ltd. has completed a Follow-on Equity Offering in the amount of CAD 11.41875 million.

Kits Eyecare Ltd. has filed a Follow-on Equity Offering.

Kits Eyecare Ltd. has filed a Follow-on Equity Offering.

Consensus EPS estimates increase by 17%

Kits Eyecare Upwards Earnings Guidance for the Third Quarter of 2024

KITS Eyecare Launches KITS Daily Color Contacts

Chief Marketing Officer recently sold CA$62k worth of stock

Kits Eyecare Ltd. (TSE:KITS) Stocks Shoot Up 28% But Its P/S Still Looks Reasonable

Second quarter 2024 earnings released: EPS: CA$0.006 (vs CA$0.038 loss in 2Q 2023)

Kits Eyecare Ltd. Provides Earnings Guidance for the Third Quarter of 2024

Price target increased by 8.6% to CA$10.75

Kits Eyecare Ltd. to Report Q2, 2024 Results on Aug 07, 2024

Kits Eyecare Ltd. Launches Pangolin Smart Glasses Line

Kits Eyecare Ltd. Launches Daily Silicone Hydrogel Contact Lens Lineup

Why Investors Shouldn't Be Surprised By Kits Eyecare Ltd.'s (TSE:KITS) 33% Share Price Surge

Kits Eyecare Ltd. Elects Andrew Reid as Director

An Intrinsic Calculation For Kits Eyecare Ltd. (TSE:KITS) Suggests It's 44% Undervalued

Kits Eyecare Ltd. Provides Earnings Guidance for the Second Quarter of 2024

First quarter 2024 earnings released: EPS: CA$0.002 (vs CA$0.033 loss in 1Q 2023)

KITS Eyecare Ltd. Announces Executive Appointments

Kits Eyecare Ltd. to Report Q1, 2024 Results on May 08, 2024

Kits Eyecare Ltd., Annual General Meeting, Jun 05, 2024

Kits Eyecare Ltd. Appoints Zhe Choo as Chief Financial Officer, Effective March 31, 2024

Chief Information Officer recently bought CA$54k worth of stock

Full year 2023 earnings: EPS misses analyst expectations

New minor risk - Profitability

Kits Eyecare Ltd. to Report Q4, 2023 Results on Mar 06, 2024

Insufficient new directors

Revenues Tell The Story For Kits Eyecare Ltd. (TSE:KITS)

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Kits Eyecare Ltd. to Report Q3, 2023 Results on Nov 08, 2023

Consensus EPS estimates upgraded to CA$0.09 loss

Co-Founder recently bought CA$275k worth of stock

Second quarter 2023 earnings: EPS misses analyst expectations

Price target increased by 14% to CA$8.33

Kits Eyecare Ltd. to Report Q2, 2023 Results on Aug 09, 2023

With Kits Eyecare Ltd. (TSE:KITS) It Looks Like You'll Get What You Pay For

New minor risk - Market cap size

First quarter 2023 earnings released: CA$0.03 loss per share (vs CA$0.072 loss in 1Q 2022)

Co-Founder recently bought CA$164k worth of stock

Price target increased by 18% to CA$5.88

Full year 2022 earnings released: CA$0.15 loss per share (vs CA$0.48 loss in FY 2021)

Kits Eyecare Ltd. Provides Revenue Guidance for the Full Year 2022

Co-Founder recently bought CA$83k worth of stock

Third quarter 2022 earnings released: EPS: CA$0.001 (vs CA$0.069 loss in 3Q 2021)

Kits Eyecare Ltd. to Report Q3, 2022 Results on Nov 09, 2022

Co-Founder recently bought CA$55k worth of stock

Co-Founder recently bought CA$98k worth of stock

Kits Eyecare Ltd. Announces Appointment of Sabrina Liak to President

Second quarter 2022 earnings released: CA$0.03 loss per share (vs CA$0.16 loss in 2Q 2021)

Kits Eyecare Ltd. to Report Q2, 2022 Results on Aug 11, 2022

Co-Founder recently bought CA$447k worth of stock

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Kits Eyecare Ltd. to Report Q1, 2022 Results on May 11, 2022

Price target decreased to CA$6.33

Co-Founder recently bought CA$620k worth of stock

Kits Eyecare Ltd., Annual General Meeting, Jun 09, 2022

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Kits Eyecare Ltd. to Report Q4, 2021 Results on Mar 09, 2022

Kits Eyecare Ltd. Names Tai Silvey as Senior Vice President of Operations

Co-Founder recently bought CA$173k worth of stock

Third quarter 2021 earnings released: CA$0.07 loss per share (vs CA$0.014 loss in 3Q 2020)

Co-Founder recently sold CA$1.7m worth of stock

Co-Founder recently bought CA$142k worth of stock

Co-Founder recently bought CA$112k worth of stock

Second quarter 2021 earnings released: CA$0.16 loss per share (vs CA$0.014 loss in 2Q 2020)